Australia-based Filamon Limited has registered a Phase Ib/IIa first-in-human clinical trial of BETA-TT8 Ophthalmic Gel 3.8%, a topical small-molecule MEK/ERK (mitogen-activated protein kinase) pathway inhibitor, in patients with neovascular age-related macular degeneration (wetAMD). The study, listed on ClinicalTrials.gov as NCT07766473 with a status of "not yet recruiting," is expected to open at four Australian sites in Q3 2026, with primary completion targeted for Q1 2027.
The open-label, randomized study will enroll 24 patients with stable wetAMD who have previously received at least three intravitreal aflibercept (Eylea) injections. Participants will be assigned in parallel groups of eight to receive BETA-TT8 at one of three dosing frequencies — once, twice, or three times daily — for 12 weeks. The dose per administration is identical across all arms; frequency is the only variable. Primary endpoints cover treatment-emergent adverse events, corneal epithelial safety, intraocular pressure changes, and dose-limiting toxicities. Exploratory secondary endpoints include aflibercept rescue injection frequency, best-corrected visual acuity change, and central subfield thickness on optical coherence tomography. Patients meeting pre-specified criteria at Week 12 may enter a 12-month open-label extension.
The topical gel format is the asset's primary differentiating feature: current standard-of-care anti-VEGF agents — including aflibercept (Eylea, Eylea HD), ranibizumab, and faricimab — require repeated intravitreal injections, which carry procedural burden and cumulative risk. A self-administered eye drop or gel that could extend injection intervals or reduce rescue injection frequency would represent a meaningful change in the treatment paradigm, though whether BETA-TT8 achieves this remains entirely unproven at this stage.
No peer-reviewed preclinical studies of BETA-TT8 were identified. Filamon has disclosed company-generated animal data, including a claim that BETA-TT8 outperformed aflibercept in a wet AMD model, but the company labels the underlying results as data on file. Filamon's corporate website lists BETA-TT8 as part of its BETA platform, which the company states targets MEK/ERK signaling in inflamed tissue across ophthalmic, oncology, and cardiovascular indications, but independent corroboration of these claims was not available.